TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32757060

Group type: EXPERIMENTAL
Intervention: Participants who listened to their favourite music (n = 20) while watching the video.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Pre‐selected classical music excerpts varying in valence and arousal (happy, peaceful, agitated, sad) (n = 40) while watching the video.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (n = 20) who watched the video without music.
Number of subjects: 80
Study: 35341443

Group type: EXPERIMENTAL
Intervention: Online physiotherapy program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active comparator (paper-based exercise program)
Number of subjects: 0
Study: 33530248

Group type: EXPERIMENTAL
Intervention: Lactic dehydrogenase-lymphocyte ratio (LLR) >345
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Lactic dehydrogenase levels
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Combination scores including LLR
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: LLR in validation cohort
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: C-reactive protein, DIC score ≥2
Number of subjects: 145
Study: 35805505

Group type: EXPERIMENTAL
Intervention: Cycling dual-task intervention (cycling combined with a cognitive task)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study: 34423619

Group type: EXPERIMENTAL
Intervention: Adductor canal block combined with transcutaneous electrical acupoint stimulation (TEAS+ACB)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Adductor canal block (ACB)
Number of subjects: 84
Study: 34081489

Group type: EXPERIMENTAL
Intervention: Active alcohol (target 0.08% breath alcohol content) and active cannabis (12.5% THC)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo alcohol and placebo cannabis
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Active alcohol and placebo cannabis
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Placebo alcohol and active cannabis
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Active alcohol and active cannabis
Number of subjects: 28
Study: 32895197

Group type: EXPERIMENTAL
Intervention: Digital positioning guide plate
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no guide plate)
Number of subjects: 30
Study: 35288386

Group type: EXPERIMENTAL
Intervention: Resistance exercise training (RET) combined with leucine and vitamin D-enriched whey protein-based oral nutritional supplement (2 times per day) for 13 weeks plus usual care
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200
Study: 32859702

Group type: EXPERIMENTAL
Intervention: SSTR-RADS 1.0 scoring by 4 masked readers
Number of subjects: 51

Group type: COMPARATOR
Intervention: SSTR-RADS 1.0 scoring by inexperienced readers
Number of subjects: 51
Study: 33181371

Group type: EXPERIMENTAL
Intervention: Voice-activated digital recording devices
Number of subjects: 20
Study: 32265425

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting balloon (PEB)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Regular balloon angioplasty (BA)
Number of subjects: 222
Study: 35291004

Group type: EXPERIMENTAL
Intervention: High-dose rifampicin (30 mg/kg) and ethambutol (R30HZE, Arm 1)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: High-dose rifampicin and levofloxacin (R30HZL, Arm 2)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Standard-dose rifampicin and ethambutol (R15HZE, Arm 3)
Number of subjects: 37
Study: 34824344

Group type: EXPERIMENTAL
Intervention: SAR341402 insulin aspart
Number of subjects: 40

Group type: COMPARATOR
Intervention: NovoRapid
Number of subjects: 40
Study: 33619183

Group type: EXPERIMENTAL
Intervention: WASH intervention arm (comprehensive water improvement and hygiene education programme)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Delayed WASH arm (control group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: WASH intervention arm
Number of subjects: 40
Study: 32249950

Group type: EXPERIMENTAL
Intervention: Electrical stimulation of denervated muscle (ESDM)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Sham electrical stimulation
Number of subjects: 38
Study: 32313928

Group type: EXPERIMENTAL
Intervention: HB-101 (low, medium, or high dose)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 32719875

Group type: EXPERIMENTAL
Intervention: Educational video
Number of subjects: 22
Study: 32164762

Group type: EXPERIMENTAL
Intervention: Peficitinib (100 mg, or 50 mg for patients transferring from RAJ1), administered orally once daily
Number of subjects: 843
Study: 35843714

Group type: EXPERIMENTAL
Intervention: Moderate intensity treadmill aerobic exercise for four weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no aerobic exercise)
Number of subjects: 22
Study: 32811171

Group type: EXPERIMENTAL
Intervention: Improving Parents As Communication Teachers
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 97
Study: 36450211

Group type: EXPERIMENTAL
Intervention: Fast Walking Group (FWG)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Moderate Walking Group (MWG)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Slow Walking Group (SWG)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control Group (CON)
Number of subjects: 76
Study: 34155812

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 100
Study: 35075049

Group type: EXPERIMENTAL
Intervention: Collagen membrane covering over BFP (Group II)
Number of subjects: 30

Group type: COMPARATOR
Intervention: BFP alone (Group I)
Number of subjects: 30
Study: 33370847

Group type: EXPERIMENTAL
Intervention: Rivastar Silver Diammine Fluoride (SDF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stabilised aqueous silver fluoride solution (AgF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rivastar Silver Diammine Fluoride (SDF) with Potassium Iodide (KI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stabilised aqueous silver fluoride solution (AgF) with Potassium Iodide (KI)
Number of subjects: 0
Study: 33493023

Group type: EXPERIMENTAL
Intervention: 40 g of hemp protein (hemp40)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 20 g of hemp protein (hemp20)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 40 g of soybean protein (soy40)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 20 g of soybean protein (soy20)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Carbohydrate control
Number of subjects: 43
Study: 32352008

Group type: EXPERIMENTAL
Intervention: Manual Dynamic Activation (MDA)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Sonic Irrigation (SI)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Passive Ultrasonic Irrigation (PUI)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Conventional Needle Irrigation (CI)
Number of subjects: 65
Study: 35577966

Group type: EXPERIMENTAL
Intervention: E-cigarettes
Number of subjects: 1140

Group type: COMPARATOR
Intervention: Nicotine patches
Number of subjects: 1140
Study: 34195577

Group type: EXPERIMENTAL
Intervention: Losartan (25 mg orally twice daily, reduced to once daily if eGFR was reduced)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 117
Study: 32862694

Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 9326

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 9326

Group type: EXPERIMENTAL
Intervention: PRECISE‐DAPT score
Number of subjects: 9326

Group type: EXPERIMENTAL
Intervention: PARIS score
Number of subjects: 9326

Group type: EXPERIMENTAL
Intervention: DAPT (bleeding component) score
Number of subjects: 9326
Study: 35180719

Group type: EXPERIMENTAL
Intervention: Topical imiquimod (6.25 mg 3 times weekly for 8 to 16 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: LLETZ (Large Loop Excision of the Transformation Zone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical imiquimod
Number of subjects: 0

Group type: COMPARATOR
Intervention: LLETZ
Number of subjects: 0
Study: 33004392

Group type: EXPERIMENTAL
Intervention: Pre-emptive voriconazole genotyping
Number of subjects: 146

Group type: COMPARATOR
Intervention: Routine practice (control)
Number of subjects: 146
Study: 36434797

Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation (PVI) alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Marshall-PLAN
Number of subjects: 0

Group type: COMPARATOR
Intervention: PVI only (for patients with SR maintained for ≥4 weeks after EC)
Number of subjects: 0
Study: 33651671

Group type: EXPERIMENTAL
Intervention: Rituximab (1000 mg, two infusions administered two weeks apart)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 57
Study: 32739962

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine (LB) 266 mg plus bupivacaine HCl 50 mg
Number of subjects: 186

Group type: COMPARATOR
Intervention: Bupivacaine HCl 50 mg alone
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine (LB) plus bupivacaine HCl
Number of subjects: 186

Group type: COMPARATOR
Intervention: Bupivacaine HCl alone
Number of subjects: 186
Study: 36078628

Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid (HA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dry Needling (DN)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ultrasound (US) + Isometric
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combined Treatment (DN + HA)
Number of subjects: 60
Study: 33446506

Group type: EXPERIMENTAL
Intervention: 8-cm 22G long peripheral catheter (LPC)
Number of subjects: 72

Group type: COMPARATOR
Intervention: 2.5-cm 22G peripheral intravenous catheter (PIVC)
Number of subjects: 72
Study: 32074248

Group type: EXPERIMENTAL
Intervention: Femoral access
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radial access
Number of subjects: 0
Study: 35754105

Group type: EXPERIMENTAL
Intervention: 1 mA cathodal tDCS over the left dorsolateral prefrontal cortex (dlPFC)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 27
Study: 32493115

Group type: EXPERIMENTAL
Intervention: High-dose heparin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard-dose heparin
Number of subjects: 30
Study: 35236778

Group type: EXPERIMENTAL
Intervention: Postbiotic lozenge
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Heat-killed probiotic lozenge
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 32366578

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34587302

Group type: EXPERIMENTAL
Intervention: Tenofovir amibufenamide (TMF) 25 mg
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate (TDF) 300 mg
Number of subjects: 1002
Study: 33593477

Group type: EXPERIMENTAL
Intervention: PPI group (sufentanil reduction if PPI<3, n=32)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (standard anesthesia, n=25)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: PPI group
Number of subjects: 57
Study: 35311721

Group type: EXPERIMENTAL
Intervention: Telerehabilitation guided by a telerehabilitation App (AppG)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Usual care (Control Group - CG)
Number of subjects: 49
Study: 32365870

Group type: EXPERIMENTAL
Intervention: 12-week physical literacy intervention
Number of subjects: 90

Group type: COMPARATOR
Intervention: Usual afterschool programming (Control)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Program leaders' training
Number of subjects: 90
Study: 35840273

Group type: EXPERIMENTAL
Intervention: Cyclic lighting system in isolation rooms (experimental group)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Standard ICU lighting system (control group)
Number of subjects: 148
Study: 34919250

Group type: EXPERIMENTAL
Intervention: Myo-Inositol (myo-Ins)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Myo-Inositol (myo-Ins) plus Oral Contraceptive Pills (OCP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral Contraceptive Pills (OCP)
Number of subjects: 0
Study: 36153239

Group type: EXPERIMENTAL
Intervention: Metal retainer
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Glass Fiber Reinforced Composite (GFRC)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Polyethylene Fiber Reinforced Composite (PFRC)
Number of subjects: 48
Study: 33249632

Group type: EXPERIMENTAL
Intervention: BREATHE (shared decision-making intervention)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Dose-matched attention control
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups (BREATHE and control)
Number of subjects: 80
Study: 34514929

Group type: EXPERIMENTAL
Intervention: Etanercept weekly (n=34)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Etanercept every other week (EOW) (n=32)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Re-escalation to etanercept weekly
Number of subjects: 66
Study: 35130256

Group type: EXPERIMENTAL
Intervention: Budesonide plus Salbutamol
Number of subjects: 100

Group type: COMPARATOR
Intervention: Salbutamol
Number of subjects: 100
Study: 36400157

Group type: EXPERIMENTAL
Intervention: Xenograft and gingival free graft
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dense polytetrafluoroethylene membrane
Number of subjects: 40

Group type: COMPARATOR
Intervention: Natural socket healing (blood clot)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Platelet rich fibrin plugs
Number of subjects: 40
Study: 33634747

Group type: EXPERIMENTAL
Intervention: Mulligan mobilization with movement (MWM)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 51
Study: 32456456

Group type: EXPERIMENTAL
Intervention: Intervention effect assessment using block randomization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual inspection of single-case data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Graphical representations for consistency assessment
Number of subjects: 0
Study: 32086359

Group type: EXPERIMENTAL
Intervention: High-volume high-intensity interval training (HIT)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Low-volume high-intensity interval training (HIT)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group with no exercise
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: High-volume HIT, Low-volume HIT, Control group
Number of subjects: 64
Study: 34089969

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (calcifediol)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32164597

Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) intervention
Number of subjects: 27
Study: 35511204

Group type: EXPERIMENTAL
Intervention: Cottonseed oil (CSO)
Number of subjects: 43
Study: 33722838

Group type: EXPERIMENTAL
Intervention: 0.2 pmol GLP‐1/kg/min
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 0.4 pmol GLP‐1/kg/min
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 0.8 pmol GLP‐1/kg/min
Number of subjects: 29

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: GLP‐1 infusions
Number of subjects: 29
Study: 33176812

Group type: EXPERIMENTAL
Intervention: Uninsured URAS
Number of subjects: 181

Group type: COMPARATOR
Intervention: Thai population
Number of subjects: 181
Study: 35232315

Group type: EXPERIMENTAL
Intervention: Novel shoes
Number of subjects: 18

Group type: COMPARATOR
Intervention: Usual shoes
Number of subjects: 18
Study: 33740382

Group type: EXPERIMENTAL
Intervention: novel SnF2 dentifrice containing the amino acid glycine
Number of subjects: 100

Group type: COMPARATOR
Intervention: negative control sodium monofluorophosphate dentifrice
Number of subjects: 100
Study: 35931879

Group type: EXPERIMENTAL
Intervention: Risankizumab 150 mg at weeks 0, 4, 8, 12, and 16 (arm 1)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Risankizumab 150 mg at weeks 0, 4, and 16 (arm 2)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Risankizumab 150 mg at weeks 0 and 12 (arm 3)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Risankizumab 75 mg at week 0 (arm 4)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo (arm 5)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Risankizumab (all arms)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Risankizumab 150 mg
Number of subjects: 185
Study: 32168992

Group type: EXPERIMENTAL
Intervention: Blocked practice of copying a novel movement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-autistic people
Number of subjects: 0
Study: 36097029

Group type: EXPERIMENTAL
Intervention: Homologous mRNA vaccination (third dose of the same mRNA)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Heterologous vector vaccination (ChAdOx1 nCoV‐19)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both vector and mRNA vaccines (third dose)
Number of subjects: 46
Study: 33738704

Group type: EXPERIMENTAL
Intervention: 3% melatonin oral gel
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 32056812

Group type: EXPERIMENTAL
Intervention: SSE + KT
Number of subjects: 36

Group type: COMPARATOR
Intervention: SSE
Number of subjects: 36
Study: 36287585

Group type: EXPERIMENTAL
Intervention: Culturally Sensitive Educational Video (CSEV)
Number of subjects: 1564

Group type: COMPARATOR
Intervention: Current information brochure
Number of subjects: 1564
Study: 34062603

Group type: EXPERIMENTAL
Intervention: Four-frequency pure-tone screener (FFS)
Number of subjects: 1665

Group type: EXPERIMENTAL
Intervention: Automated method for testing of auditory sensitivity (AMTAS)
Number of subjects: 1665

Group type: EXPERIMENTAL
Intervention: Digits-in-noise test (DIN)
Number of subjects: 1665

Group type: COMPARATOR
Intervention: Control group (no hearing screening)
Number of subjects: 1665
Study: 32781849

Group type: EXPERIMENTAL
Intervention: Screw and staple-plate (2 screws and an 18-mm nitinol staple)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Single 5.5-mm cannulated screw
Number of subjects: 20
Study: 36090631

Group type: EXPERIMENTAL
Intervention: Claw-suture localization device
Number of subjects: 411

Group type: COMPARATOR
Intervention: Hookwire localization device
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Claw-suture localization device (multiple localization subgroup)
Number of subjects: 411
Study: 32690074

Group type: EXPERIMENTAL
Intervention: Nasal irrigation with budesonide (1mg/2mL diluted in 250mL of physiological saline 9°/00) for 30 days, along with olfactory rehabilitation twice a day.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Nasal irrigation with physiological saline 9°/00 only for 30 days, along with olfactory rehabilitation twice a day.
Number of subjects: 120
Study: 34555031

Group type: EXPERIMENTAL
Intervention: HD204
Number of subjects: 119

Group type: COMPARATOR
Intervention: EU-sourced bevacizumab
Number of subjects: 119

Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 119
Study: 36194987

Group type: EXPERIMENTAL
Intervention: Fitspiration TikTok videos
Number of subjects: 120

Group type: COMPARATOR
Intervention: Art control TikTok videos
Number of subjects: 120
Study: 33507712

Group type: EXPERIMENTAL
Intervention: enterade®
Number of subjects: 114

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 114
Study: 35709234

Group type: EXPERIMENTAL
Intervention: Anodal tDCS over the left DLPFC
Number of subjects: 18

Group type: COMPARATOR
Intervention: Cathodal tDCS over the left DLPFC
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham tDCS over the left DLPFC
Number of subjects: 18
Study: 34324433

Group type: EXPERIMENTAL
Intervention: MR‐proADM
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: NT‐proBNP
Number of subjects: 126
Study: 32185856

Group type: EXPERIMENTAL
Intervention: Collagen membrane with 1:1 autogenous and anorganic bovine bone mineral (ABBM) mixture
Number of subjects: 20

Group type: COMPARATOR
Intervention: Titanium mesh with 1:1 autogenous and anorganic bovine bone mineral (ABBM) mixture
Number of subjects: 20
Study: 33556290

Group type: EXPERIMENTAL
Intervention: ReDO-10 programme
Number of subjects: 21
Study: 33287597

Group type: EXPERIMENTAL
Intervention: Vocational rehabilitation intervention provided by municipal social workers (n=83)
Number of subjects: 347

Group type: COMPARATOR
Intervention: Usual municipal RTW management (n=264)
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Vocational rehabilitation intervention for participants with breast cancer (n=290)
Number of subjects: 347
Study: 32003278

Group type: EXPERIMENTAL
Intervention: 0.375% bupivacaine with epinephrine (group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine (group R)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mixture of 0.5% bupivacaine with epinephrine and 2% lignocaine (group BL)
Number of subjects: 60
Study: 33938371

Group type: EXPERIMENTAL
Intervention: 6‐(Methylsulfinyl)hexyl isothiocyanate (6‐MSITC) 9 mg/day
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 34279726

Group type: EXPERIMENTAL
Intervention: IV metoprolol
Number of subjects: 270
Study: 33966396

Group type: EXPERIMENTAL
Intervention: Personalized rehabilitation exercises for 6 months
Number of subjects: 93

Group type: COMPARATOR
Intervention: Routine nursing and rehabilitation training
Number of subjects: 93
Study: 33333734

Group type: EXPERIMENTAL
Intervention: INSIGHTS intervention
Number of subjects: 127

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 127
Study: 34799113

Group type: EXPERIMENTAL
Intervention: 3× feeding frequency (0700, 1600, and 2200 h)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 0.76 kg of solid per day (high feeding rate)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 3× feeding frequency
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 0.65 kg of solid per day (low feeding rate)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Increasing feeding frequency
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Increased milk replacer allowance
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Acetaminophen (50 mg/kg of BW) mixed with MR
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Chromic oxide as the external marker
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Feeding frequency and feeding rate treatments
Number of subjects: 48
Study: 34794236

Group type: COMPARATOR
Intervention: Multiple-dose ACT-1004-1239 (30-200 mg o.d. in humans; 1-100 mg/kg b.i.d. in mice)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0